EUCTR2011-001437-16-DE进行中（未招募）1 期
A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 422
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients eligible for inclusion in this study have to fulfill the following criteria:
- •Written informed consent must be obtained before any assessment is performed
- •Male and female patients aged 18-55 years inclusive
- •A diagnosis of MS as defined by the 2005 revision to the McDonald criteria with a relapsingremitting
- •MS disease duration of more than one year (from diagnosis of MS) before study entry (Screening) Participants of the reference group eligible for inclusion have to fulfill the following criteria:
- •Written informed consent must be obtained before any assessment is performed
- •Male and female subjects aged 18-55 years inclusive
- •Matched to MS patients recruited in terms of age (±3 years),
- •ethnicity, gender and visual refraction (±2 diopters) with the MS patients recruited.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 420
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. HIV or any other known immunodeficiency syndrome (disease or drug-induced)
- •2. Any ophthalmologic reason for RNFL pathology other than MS, such as: optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment or • history or presence of severe myopia: a. in patients who have not had refractive surgery, a refractive error of greater than 6.00 diopters b. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma c. in patients that have had previous refractive surgery, an axial eye length of greater than 26 mm
- •3. Acute optic neuritis within the past 6 months before Baseline
- •4. Evidence of advanced, non-proliferative or proliferative diabetic retinopathy
- •5. Presence of retinal conditions associated with edema, subretinal fluid, cysts, etc.
- •6. History of a severe head trauma
- •7. Any of the following neurologic/psychiatric disorders:
- •history of substance abuse (drug or alcohol) in the past five years or any other factor (i.e., serious psychiatric condition) that may interfere with the subject’s ability to cooperate and comply with the study procedures • specific MRI findings (tumor, subdural haematoma, post-contusional changes, territorial stroke, neurodegenerative disorders, aneurysm/arteriovenous malformation, evidence of past macroscopic haemorrhage, or other relevant MRI findings that would interfere with evaluation) • progressive neurological disorder, other than MS, which may affect participation in the study
- •8. Concomitant use of drugs that may directly affect retinal structure and function (e.g. chronic systemic corticosteroids [>30 consecutive days; doses higher than Cushing threshold e.g. prednisone 7.5mg/d], intraocular anti-angiogenic drugs [ranibizumab, bevacizumab], intraocular steroids etc.)
- •9. Any medically unstable condition, progressive disease (other than MS) or other condition that would preclude reliable participation in the study as assessed by the investigator
- •10. Patients unable to undergo MRI scans including gadolinium enhancement:
- •reduced renal clearance (eGFR <45 ml/min) • history of severe hypersensitivity to gadolinium-DTPA • claustrophobia that cannot be overcome otherwise
- •11. Patients who have received an investigational drug or therapy within 30 days or 5 half lives, which ever is longer, of the baseline visit. No additional exclusions may be applied by the investigator, in order to ensure that the population will be representative of all eligible patients. Participants of the reference group fulfilling any of the following criteria are not eligible for inclusion in this study:
- •1. HIV or any other known immunodeficiency syndrome (disease or drug-induced)
- •2. Any ophthalmologic reason for RNFL pathology other than MS, such as: • optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment or • history or presence of severe myopia:
- •a. in subjects who have not had refractive surgery, a refractive error of greater than 6.00 diopters b. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma c. in subjects that have had previous refractive surgery, an axial eye length of greater than 26 mm
- •3. Acute optic neuritis within the past 6 months before Baseline
- •4. Evidence of advanced, non-proli
研究者
相似试验
已完成
3 期
A 3-year, multi-center study to evaluate optical coherencetomography as an outcome measure in patients with multiple sclerosischronic impairment of the central nervous system1003006410007951multiple sclerosisNL-OMON37946ovartis20
已完成
不适用
Optical Coherence Tomography (OCT) Trial in Multiple SclerosisRRMSMultiple SclerosisNCT02907281Novartis Pharmaceuticals414
已完成
不适用
A multicenter study on the evaluation of eye lens doses for medical staff performing non-vascular interventional radiology proceduresot applicableJPRN-UMIN000014941Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University100
已完成
3 期
To assess the ability of retina specialists to successfully administer Aflibercept in eye.CTRI/2023/10/059113Biosimilar collaborations Ireland Limited35
进行中（未招募）
1 期
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-006132-24-GBovartis Pharma Services AG105